Senseonics Holdings, Inc.

Medical Devices • Healthcare • Germantown, MD, United States • SENS (NMS)

301 515 7260 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005, United States

Quarter: Q4 2025 Reported: October 7, 2025 Sentiment: Positive

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

Analysis Summary

Senseonics Holdings, Inc. provided a business update for the third quarter of 2025, reporting preliminary, unaudited revenue of approximately $8.1 million. This figure represents a substantial 91% increase compared to the third quarter of 2024, indicating strong market acceptance and operational execution. The primary driver for this revenue growth was a remarkable 160% increase in new patient adoption within the U.S. market over the prior year, highlighting successful commercial strategies and growing demand for the company's continuous glucose monitoring solutions.

**Financial Performance Breakdown:**
- **Revenue:** Preliminary unaudited revenue for Q3 2025 was $8.1 million, a 91% increase year-over-year.
- **Earnings/EPS:** Not provided in this preliminary update.
- **Guidance:** No specific forward guidance for future quarters or the full year was provided in this document.

**Strategic Initiatives and Business Segment Analysis:**
- The significant new patient growth in the U.S. suggests effective marketing, sales, and potentially improved product awareness or access. This indicates a successful focus on expanding the user base for their core product offerings.

**Management Commentary and Forward Guidance:**
- The report is a preliminary business update, not a full earnings call transcript, so detailed management commentary or specific forward guidance beyond the revenue figure was not included. The update was issued via a press release as an 8-K filing.

**Competitive Positioning and Market Trends:**
- While not explicitly detailed in this filing, the strong patient growth suggests Senseonics is effectively competing in the continuous glucose monitoring (CGM) market, potentially gaining market share or benefiting from overall market expansion. The growth rate significantly outpaces general market trends for many medical device sectors.

**Risk Factors and Concerns Raised:**
- The most prominent risk factor highlighted is that the financial information is 'preliminary, unaudited' and 'subject to change.' There is 'no assurance that the Company’s actual reviewed financial results... will not differ from the preliminary financial information.'
- Uncertainties inherent in the financial close process and review by independent auditors are explicitly mentioned.
- General risk factors from previous 10-K and 10-Q filings are referenced, but not detailed in this specific report.

**Analyst Q&A Highlights:**
- As this is an 8-K filing announcing preliminary results, there was no analyst Q&A session.

Key Highlights

• Preliminary Q3 2025 revenue reached approximately $8.1 million.
• Revenue increased by a significant 91% compared to Q3 2024.
• U.S. new patient growth surged by approximately 160% year-over-year.
• The reported financial figures are preliminary and unaudited, subject to change.
• Strong patient adoption is the primary driver of revenue growth.

Financial Metrics

eps

N/A

YoY: N/A

revenue

8.1 million

YoY: 91%

guidance

net income

N/A N/A

YoY: N/A

Stock Performance (90 Days)

Data through Dec 26, 2025

Positive Signals

• Strong preliminary revenue growth of 91% year-over-year.
• Exceptional 160% increase in new U.S. patient adoption.
• Positive business update indicating operational momentum.
• Effective commercial strategy suggested by patient growth.

Risks & Concerns

— Financial information is preliminary and unaudited, subject to change.
— Uncertainties inherent in the financial close process.
— Potential for actual reviewed financial results to differ from preliminary estimates.
— Reliance on general risk factors detailed in prior 10-K and 10-Q filings.